GDNF and Parkinson disease: A number of clinical trials of CED of soluble therapeutic agents have been reported in recent years, including chemotherapies for malignant glioma (topotecan, traberdersan, nimustine) and glial cell line-derived neurotrophic factor (GDNF) for Parkinson's disease [3,4,24,25].